China
BRL Medicine 邦耀生物 is a China-based biopharmaceutical company founded in 2013. The company is dedicated to pioneering breakthroughs in human therapeutics through innovation in gene editing. With an emphasis on commercializing novel medical solutions, BRL Medicine has established itself as a leader in this domain.
Over the years, BRL Medicine has achieved significant milestones, including setting up the Shanghai Research Center for Gene Editing and Cell Therapy in collaboration with a university, obtaining over 100 patent achievements, and commencing Investigator-Initiated Clinical Trials (IIT) in numerous esteemed hospitals in China.
One of their notable achievements includes the successful development of gene editing projects for conditions such as β-thalassemia, PD1 knockout non-viral targeted integration CAR-T, and UCART, all of which have demonstrated promising clinical outcomes. Additionally, the company has contributed to renowned academic journals such as Nature Medicine and Nature Biotechnology, showcasing their commitment to advancing the field.
At the core of its operations, BRL Medicine has established five technology platforms with independent intellectual property rights, bolstering their capabilities in gene editing, hematopoietic stem cells, CAR-T therapy, universal cells, and enhanced T cell platforms. Supported by a 7000 square meter GMP pilot plant and a team of over 200 professionals, the company is equipped to facilitate the rapid transformation and application of its innovative research.
Notably, BRL Medicine's latest milestone was marked by its Series B investment on 14 November 2022, which saw the participation of prominent investors such as Beta Fund, Gopher Asset Management, Oriental Fortune Capital, FTZ Fund, and Tasly Capital. This injection of capital reflects investor confidence in the company's vision and potential for global impact.
With an unwavering commitment to addressing the needs of patients and leveraging clinical feedback, BRL Medicine is actively driving the rapid innovation and iteration of its R&D products. The company's collaborative approach and partnerships with global biomedical ecosystem players underscore its openness, inclusivity, and determination to positively impact individuals globally affected by genetic disorders and cancer.
